Moleculin Posts Wider-Than-Expected $9.59/Share Loss as Cash Runs Thin
MBRX has more than doubled off its 52-week low of $3.228 on light trading volume (0.2× avg).
Summary
Moleculin reported a Q3 adjusted loss of $9.59 per share, worse than the $8.87 consensus of three analysts, on zero revenue as expected. The quarterly net loss was $7.27 million. The company held just $7.3 million of cash at September 30 and said that is not enough to fund a year of operations, per the 10-Q filed earlier today. That cash position is the real issue: this is a micro-cap with a going-concern overhang and a Nasdaq panel exception running to March 15, 2027, following the 1-for-20 reverse split that took effect October 20. The offsetting story is clinical — the first interim MIRACLE AML look showed 43% and 36% complete remission rates in the two Annamycin arms, and the abstract was accepted for the December ASH meeting. Shares are down 87.8% year to date. Watch the full 90-patient MIRACLE Part A readout and the ASH presentation in December for the next real datapoint.
At the time of this announcement, MBRX was trading at $7.87 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $8.3M. The 52-week trading range was $3.23 to $243.80. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: Reuters.